No profile data available.
Alector, Inc. (ALEC) is a healthcare company in the brain and nerve treatment drugs industry, based in South San Francisco, United States, with about 103 full-time employees.
It reported revenue of $21.05 million for fiscal year 2025, down 79.1% from fiscal year 2024, and net income of -$142.93 million. Its market capitalization was $232.25 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Alector reported $21.05 million in revenue for fiscal year 2025, down 79.1% from $100.56 million in fiscal year 2024.
$232.25 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Vanda Pharmaceuticals Inc. (VNDA), Inhibikase Therapeutics, Inc. (IKT), AC Immune SA (ACIU), Entrada Therapeutics, Inc. (TRDA).